Limb-girdle muscular dystrophy

1. High-Yield Summary

• Definition & Clinical Spectrum: Limb-girdle muscular dystrophies (LGMDs) represent a genetically and clinically heterogeneous collective of rare, progressive inherited myopathies characterized by primary, symmetrical muscle weakness and wasting predominantly affecting the pelvic and shoulder girdles, with characteristic sparing of facial and extraocular musculature in classic presentations.
• Genomic Architecture & Modern Nomenclature: Encompasses more than 30 distinct monogenic entities classified under the 229th ENMC International Consensus criteria into autosomal dominant (LGMDD, <10% of cases) and autosomal recessive (LGMDR, >90% of cases) subtypes based on inheritance pattern and primary causative mutated gene (e.g., LGMDR1 for CAPN3, LGMDR2 for DYSF, LGMDR3-R6 for sarcoglycans, LGMDR9 for FKRP, and LGMDD1 for LMNA).
• Subtype-Specific Cardiopulmonary Lethality: Subtype identification is life-critical; laminopathies (LMNA / LGMDD1) and sarcoglycanopathies (SGCA/B/G/D / LGMDR3-R6) exhibit high penetrance of fatal cardiac conduction blocks, malignant ventricular arrhythmias, and dilated cardiomyopathy requiring early prophylactic device therapy, whereas fukutin-related protein (FKRP / LGMDR9) and titin (TTN / LGMDR10) variants carry substantial risks of disproportionate, occult diaphragmatic failure and nocturnal hypoventilation.
• Orthopaedic Principles & Functional Preservation: Orthopaedic interventions focus on prolonging upright ambulation, correcting fixed soft-tissue contractures (Achilles tendon, hamstrings, iliotibial band), stabilizing progressive neuromuscular spinal deformities (Cobb angle >40°–50°), and restoring scapular fixation (scapulothoracic arthrodesis/scapulopexy) to augment upper extremity functional reach, balanced strictly against the critical hazard of rapid, irreversible disuse muscle atrophy from prolonged recumbency.
• Universal Anesthetic Contraindications (Strict TIVA Mandate): Total intravenous anesthesia (TIVA) using propofol, remifentanil, and non-depolarizing neuromuscular blockers with sugammadex reversal is universally mandatory; depolarizing muscle relaxants (succinylcholine) and all volatile halogenated inhalational agents are strictly contraindicated due to lethal risks of massive acute rhabdomyolysis, hyperkalemic cardiac arrest, and malignant hyperthermia-like reactions.

2. Anatomy

Limb-girdle muscular dystrophy selectively compromises the functional kinetic chains of the proximal shoulder and pelvic girdles, while distal musculature remains comparatively preserved during early disease stages. Understanding the exact mechanical force couples, neurovascular anatomy, and underlying molecular sarcolemmal architecture is essential for diagnostic precision and surgical planning.

Functional Anatomy of the Shoulder Girdle: Dynamic stabilization of the scapulothoracic articulation relies on an intricate muscular force couple. The serratus anterior (innervated by the long thoracic nerve from C5, C6, and C7) anchors the medial border of the scapula against the posterior thoracic cage and drives upward scapular rotation during arm elevation. The trapezius (innervated by the spinal accessory nerve, cranial nerve XI, with proprioceptive fibers from C3 and C4) supports the shoulder girdle and coordinates scapular retraction, elevation, and upward rotation. The rhomboid major and minor (innervated by the dorsal scapular nerve, C5) retract and stabilize the medial scapular border. In LGMD subtypes involving the shoulder girdle, preferential atrophy of the serratus anterior, trapezius, and rhomboids disrupts this dynamic balance, producing prominent medial or lateral scapular winging. Loss of stable scapular fixation deprives the deltoid and rotator cuff of a rigid mechanical fulcrum, severely restricting active overhead forward elevation and abduction despite preserved glenohumeral musculature.

Functional Anatomy of the Pelvic Girdle and Lower Extremity: Pelvic stability during stance and gait depends on three primary muscular complexes:

• Hip Abductor Complex: The gluteus medius and gluteus minimus (innervated by the superior gluteal nerve, L4, L5, S1) prevent contralateral pelvic sag during single-leg stance. Dystrophic weakness produces an uncompensated pelvic drop toward the swing leg (positive Trendelenburg sign) and prompts compensatory lateral trunk lean over the stance limb (gluteal lurch or waddling gait).
• Hip Extensor Complex: The gluteus maximus (innervated by the inferior gluteal nerve, L5, S1, S2) controls hip extension at heel strike. Muscle wasting induces a posterior trunk lean to position the body center of mass posterior to the hip joint axis, biomechanically locking the hip in extension to prevent anterior collapse.
• Knee Extensor & Ankle Muscle Complexes: The quadriceps femoris (innervated by the femoral nerve, L2, L3, L4) provides dynamic knee stability. Quadriceps weakness leads to sudden knee buckling, which patients compensate for by walking with knee hyperextension (genu recurvatum) and trunk forward pitch. Concurrently, imbalance between weakened ankle dorsiflexors and fibrotic shortening of the gastrocnemius-soleus complex produces fixed equinus contractures, further impairing tibial advancement during stance.

Molecular Sarcolemmal Architecture: The sarcolemma of striated muscle fibers contains specialized multiprotein complexes that confer structural resistance against contraction-induced mechanical shear stress and regulate intracellular signaling:

• Dystrophin-Glycoprotein Complex (DGC): A transmembrane structural axis bridging the intracellular F-actin cytoskeleton (via dystrophin) to the extracellular basal lamina (laminin-211 via alpha- and beta-dystroglycan), absorbing mechanical shock during muscle shortening and lengthening.
• Sarcoglycan Subcomplex: A heterotetrameric transmembrane assembly composed of alpha-, beta-, gamma-, and delta-sarcoglycans (encoded by SGCA, SGCB, SGCG, and SGCD). The sarcoglycan complex associates tightly with beta-dystroglycan and sarcospan at the sarcolemma; loss or missense mutation of any single sarcoglycan subunit destabilizes the entire tetramer, precipitating sarcolemmal fragility and secondary sarcoglycan deficiency.
• Dysferlin: A 230-kDa single-pass transmembrane protein (encoded by DYSF on chromosome 2p13) enriched at the sarcolemma and intracellular cytoplasmic vesicles. Dysferlin functions as a calcium-activated membrane patch repair engine, interacting with annexins A1 and A2 to orchestrate vesicle fusion and seal sarcolemmal microtears generated during muscle contraction.
• Calpain-3: A muscle-specific, non-lysosomal calcium-dependent cysteine protease (encoded by CAPN3 on chromosome 15q15) tethered to the giant sarcomeric ruler titin at the N2A and M-line regions. Calpain-3 regulates sarcomeric remodeling, mechanosensory signaling, and the turnover of cytoskeletal intermediate filaments.
• Titin: A giant sarcomeric structural protein (encoded by TTN on chromosome 2q31) spanning from the Z-disc to the M-line that functions as a bidirectional molecular spring, conferring passive myofibrillar elasticity and maintaining sarcomeric alignment during active contraction.
• Lamin A/C: Type V intermediate filament proteins (encoded by LMNA on chromosome 1q22) located along the inner nuclear membrane, providing structural integrity to the nuclear envelope, regulating chromatin architecture, and protecting the nucleus against mechanical shear forces.

Surgical Corridors and Neurovascular Danger Zones: Operative interventions in LGMD require precise knowledge of adjacent neurovascular structures:

• Achilles Tendon Lengthening: The sural nerve and lesser saphenous vein course 1.0 to 1.5 cm lateral to the Achilles tendon in the distal third of the lower leg; aggressive lateral dissection or unguided percutaneous tenotomy risks sural nerve laceration or painful neuroma formation. Medially and deep to the flexor retinaculum within the tarsal tunnel lie the tibial nerve and posterior tibial vessels.
• Hamstring & Iliotibial Band (ITB) Release: The common peroneal (fibular) nerve courses directly posterior and medial to the biceps femoris tendon before wrapping around the fibular neck; during distal biceps tenotomy or lateral ITB fasciotomy (Yount procedure), the common peroneal nerve is susceptible to direct transection, thermal damage, or traction injury. Centrally, the sciatic nerve lies deep between the semimembranosus and biceps femoris.
• Posterior Spinal Instrumentation: During exposure and pedicle screw instrumentation for neuromuscular scoliosis, lateral or anterior pedicle screw breach threatens the descending thoracic aorta on the left, the azygos vein on the right, and the parietal pleura. Medial or inferior breach violates the spinal canal or neural foramen, injuring the cord, conus medullaris, or exiting nerve roots. Segmental radicular vessels, including the artery of Adamkiewicz (typically originating between T9 and L1 on the left), must be preserved along the lateral vertebral walls.
• Scapulothoracic Fusion / Scapulopexy: Sublaminar cable passage or rib cerclage around ribs 3 to 6 carries high risks of pleural puncture, pneumothorax, and pulmonary laceration. Along the inferior margin of each rib within the subcostal groove lie the intercostal vein, artery, and nerve. Along the medial scapular border, the dorsal scapular nerve and artery (deep to the rhomboids) and the spinal accessory nerve (coursing deep to the anterior surface of the trapezius) must be carefully identified and protected.

3. Pathogenesis

The pathogenesis of limb-girdle muscular dystrophy centers on mechanical membrane disruption, defective sarcolemmal repair, aberrant intracellular calcium homeostasis, and progressive fibrofatty muscle degeneration.

Mechanical Sarcolemmal Disruption: Muscle contraction, particularly eccentric lengthening loading, imposes substantial physical tension across the sarcolemma. In healthy myofibers, the dystrophin-glycoprotein complex and associated sarcoglycans dissipate this stress into the extracellular matrix. When sarcoglycan subunits are deficient or titin elasticity is impaired, contractile force transmits directly to the lipid bilayer, producing microtears in the sarcolemma.

Defective Membrane Resealing: In healthy muscle, acute sarcolemmal microtears trigger a localized influx of extracellular calcium that immediately recruits cytoplasmic dysferlin-bearing vesicles to the lesion site. Dysferlin interacts with annexins A1 and A2 to mediate emergency vesicle-vesicle and vesicle-membrane fusion, forming a protective repair patch within seconds. In dysferlinopathy (LGMDR2), this calcium-activated membrane resealing mechanism is abolished; sarcolemmal breaches remain patent, leading to continuous sarcoplasmic leakage and progressive cell death.

Intracellular Calcium Overload & Calpain Hyperactivation: Persistent sarcolemmal permeability triggers a massive, uncontrolled influx of extracellular calcium into the sarcoplasm, overwhelming physiological calcium-buffering mechanisms including sarcoplasmic reticulum SERCA pumps and parvalbumin. Pathologic cytosolic hypercalcemia activates neutral cysteine proteases (calpains) and calcium-dependent phospholipases, which indiscriminately proteolyze sarcomeric titin, troponin, and desmin intermediate filaments, degrading the contractile apparatus.

Mitochondrial Dysfunction & Energetic Failure: Sustained cytosolic calcium elevation drives excessive calcium entry into the mitochondrial matrix via the mitochondrial calcium uniporter (MCU). Mitochondrial calcium overload triggers opening of the high-conductance mitochondrial permeability transition pore (mPTP), dissipating the inner mitochondrial membrane electrical gradient. This results in uncoupling of oxidative phosphorylation, cessation of ATP synthesis, release of cytochrome c into the cytoplasm, and execution of necrotic and apoptotic death cascades.

Myofiber Necrosis, Inflammation, and Fibrofatty Replacement: Necrotic myofibers release intracellular damage-associated molecular patterns (DAMPs) such as HMGB1 and heat shock proteins, provoking chronic endomysial inflammation dominated by CD4+ and CD8+ T lymphocytes and M1 macrophages. Although resident satellite cells initially attempt regeneration, persistent ongoing necrosis exhausts the satellite cell pool over time. Unchecked signaling by transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) stimulates fibroadipogenic progenitors (FAPs) to proliferate and differentiate into myofibroblasts and adipocytes, replacing contractile muscle with dense collagenous fibrosis and adipose tissue.

4. Natural History

Epidemiology: Limb-girdle muscular dystrophies represent the fourth most prevalent category of hereditary myopathies (surpassed only by Duchenne/Becker dystrophies, myotonic dystrophy, and facioscapulohumeral dystrophy), with an estimated pooled global prevalence between 1.63 and 2.27 per 100,000 individuals. Autosomal recessive subtypes (LGMDR) account for more than 90% of cases, while autosomal dominant variants (LGMDD) represent under 10%. Calpainopathy (LGMDR1), dysferlinopathy (LGMDR2), and fukutin-related protein dystrophy (LGMDR9) constitute the most common recessive subtypes worldwide, with notable geographic enrichment driven by founder mutations (e.g., LGMDR1 in the Basque population and Russia, LGMDR2 in Japan and the Middle East, and LGMDR9 in Northern Europe).

Age of Onset Across Subtypes:

• Childhood-Onset (<10 Years): Sarcoglycanopathies (LGMDR3, LGMDR4, LGMDR5, LGMDR6) classically present between ages 3 and 8 with an aggressive, Duchenne-like course featuring delayed motor milestones, frequent tripping, difficulty running, and early calf pseudohypertrophy. Early-onset calpainopathy (LGMDR1) can also manifest in late childhood with toe-walking and pelvic girdle weakness.
• Adolescent-to-Young Adult Onset (15–30 Years): Dysferlinopathy (LGMDR2) characteristically manifests between ages 15 and 25, presenting either as a proximal limb-girdle weakness or as a distal posterior calf phenotype (Miyoshi myopathy) with inability to stand on tiptoes; classic calpainopathy (LGMDR1) and fukutin-related protein dystrophy (LGMDR9 / FKRP) commonly present during this window.
• Adult-to-Late Onset (>30–50 Years): Laminopathies (LGMDD1 / LMNA), DNAJB6-related myopathy (LGMDD2), and late-onset titinopathies (LGMDR10) typically present with insidious, slowly progressive proximal weakness in the fourth to sixth decades of life.

Ambulatory Trajectory & Loss of Ambulation: The rate of functional decline correlates directly with the specific genetic defect and age of symptom onset. Patients with childhood-onset sarcoglycanopathies experience rapid progression, typically losing independent ambulation between 12 and 16 years of age. In contrast, patients with adolescent-onset calpainopathy, dysferlinopathy, or FKRP-related dystrophy exhibit an intermediate trajectory, maintaining ambulation for 15 to 25 years following symptom onset before transitioning to wheelchair dependence in the third to fifth decades. Dominant subtypes (LGMDD1, LGMDD2) follow a slow, protracted course, with many individuals remaining ambulatory well into late adulthood.

Respiratory Insufficiency: Progressive involvement of the diaphragm and accessory intercostal muscles causes restrictive ventilatory impairment, characterized by an insidious reduction in forced vital capacity (FVC), nocturnal hypoventilation, sleep-disordered breathing, and eventual hypercapnia. Diaphragmatic weakness is particularly pronounced in LGMDR9 (FKRP), LGMDR10 (TTN), and LGMDR1 (CAPN3). Notably, in FKRP-related dystrophy, severe diaphragmatic failure can develop disproportionately early while patients remain fully ambulatory, highlighting the need for routine pulmonary surveillance.

Cardiomyopathy & Lethal Arrhythmias: Subtype-specific cardiac involvement is a major determinant of mortality:

• Laminopathies (LGMDD1 / LMNA): Exhibit high age-dependent penetrance (>80% by age 50) of life-threatening cardiac disease. Pathologic features include progressive atrioventricular (AV) nodal conduction delays (first-, second-, and third-degree heart block), sinus arrest, atrial fibrillation/flutter, malignant ventricular tachyarrhythmias (ventricular tachycardia and ventricular fibrillation), and progressive dilated cardiomyopathy. Sudden cardiac death can occur even in patients with mild or subclinical skeletal muscle weakness.
• Sarcoglycanopathies (LGMDR3–R6): Dilated cardiomyopathy with congestive heart failure occurs in 20% to 40% of patients, particularly in beta-sarcoglycan (LGMDR4) and delta-sarcoglycan (LGMDR6) deficiencies.
• Fukutin-Related Protein Dystrophy (LGMDR9 / FKRP): Dilated cardiomyopathy and progressive left ventricular systolic dysfunction develop in 20% to 30% of adult patients, often correlating with the severity of skeletal muscle weakness.

5. Clinical Presentation

History

Eliciting a detailed clinical history is essential for narrowing the differential diagnosis and uncovering subclinical cardiopulmonary complications:

• Functional Loss of Pelvic Girdle: Difficulty rising from low chairs, climbing stairs, or getting out of a car without using arms for support; loss of running and jumping ability; frequent unprovoked falls; and complaints of progressive gait instability.
• Functional Loss of Shoulder Girdle: Inability to lift arms above shoulder level, fatigue during overhead activities such as styling hair or reaching high shelves, difficulty carrying heavy objects, and noticeable winging of the shoulder blades noticed by family members or athletic coaches.
• Exercise Intolerance & Myoglobinuria: Severe muscle cramping, post-exertional myalgia, and episodic dark tea- or cola-colored urine following strenuous exercise (frequently reported in dysferlinopathy and calpainopathy).
• Multigenerational Family Pedigree: Inquire specifically about parental consanguinity (strongly points to autosomal recessive inheritance, LGMDR) versus vertical transmission across successive generations (points to autosomal dominant inheritance, LGMDD). Document any family history of early pacemaker implantation, unexplained heart failure, or sudden unexpected death at young ages.
• Cardiac Symptoms: Palpitations, episodic lightheadedness, presyncope, syncope, or reduced exertional tolerance disproportionate to skeletal weakness (critical red flags for LMNA or sarcoglycan mutations).
• Nocturnal Hypoventilation Symptoms: Waking morning headaches, excessive daytime somnolence, unrefreshing sleep, frequent nighttime awakenings, orthopnea, and impaired daytime concentration.

Physical Exam

Physical examination must systematically evaluate muscle bulk, provocative maneuvers, joint contractures, and axial alignment:

• Gowers’ Sign: The patient is asked to rise from a seated or supine position on the floor. Due to severe gluteal and quadriceps weakness, the patient assumes a prone position, flexes the hips and knees, places hands on the floor, and sequentially “walks” hands up the shins, knees, and thighs to push the trunk into an upright posture [Sensitivity ~90%, Specificity ~82% in pelvic girdle dystrophy].
• Scapular Winging Test: The patient performs a wall push-up or actively elevates arms forward to 90° against light downward resistance. Insufficiency of the serratus anterior and periscapular stabilizers produces prominent medial or lateral elevation of the vertebral border and inferior angle of the scapula off the posterior thoracic wall [Sensitivity ~88%, Specificity ~85% for periscapular stabilizer failure].
• Trendelenburg Test: The patient stands unipedal on the affected limb for 30 seconds. Inability of the gluteus medius and minimus to support the pelvis causes the contralateral pelvis to sag downward [Sensitivity ~80%, Specificity ~78% for hip abductor insufficiency].
• Myopathic Gait Assessment: Dynamic inspection demonstrates a wide-based, hyperlordotic stance with bilateral compensatory lateral trunk shifting over the weightbearing limb (waddling gait) and toe-walking.
• Calf Pseudohypertrophy: Palpation of the gastrocnemius muscles reveals prominent, symmetrical enlargement with a characteristic firm, rubbery consistency resulting from extensive fibrofatty infiltration rather than true muscle hypertrophy (frequent in sarcoglycanopathies and FKRP).
• Silfverskiöld Test: Passive ankle dorsiflexion is evaluated with the knee flexed to 90° and repeated with the knee in full extension. If dorsiflexion is restricted only with the knee extended, isolated gastrocnemius contracture is present; if dorsiflexion is equally restricted regardless of knee position, combined gastrocnemius-soleus contracture is diagnosed.
• Thomas Test: The patient lies supine, and the contralateral hip is maximally flexed to flatten the lumbar spine. Inability of the extended test thigh to lie flat on the examination table confirms fixed hip flexion contracture.
• Ober Test: The patient is placed in the lateral decubitus position with the pelvis stabilized. The upper hip is abducted and extended, then lowered toward the table. Inability of the knee to adduct past the horizontal plane confirms fixed contracture of the iliotibial band and tensor fasciae latae.
• Spinal Alignment & Pelvic Obliquity: Formal assessment of the spine in both sitting and standing positions evaluates for rigid thoracic scoliosis, compensatory lumbar hyperlordosis, loss of sagittal balance, and fixed pelvic obliquity.

6. Imaging and Diagnostic Studies

Modern diagnostic workup follows an orderly hierarchy, progressing from biochemical testing to high-resolution imaging, definitive molecular genomics, and cardiopulmonary profiling:

• Serum Creatine Kinase (CK):
  Massive Elevation (>10x to 100x ULN, 5,000 to >20,000 U/L): Cardinal feature of dysferlinopathy (LGMDR2), sarcoglycanopathies (LGMDR3-R6), and early-stage calpainopathy (LGMDR1); marked hyperCKemia is frequently detected presymptomatically.
  Moderate Elevation (2x to 5x ULN, 500 to 2,000 U/L): Characteristic of laminopathy (LGMDD1), late-stage calpainopathy, and advanced burned-out dystrophies.
  Normal to Mildly Elevated CK (<2x ULN): Observed in select adult-onset dominant forms, notably DNAJB6-related myopathy (LGMDD2).
• Whole-Body Muscle MRI (T1-Weighted, STIR, and Dixon Sequences): Whole-body MRI serves as the primary non-invasive pattern-recognition tool, distinguishing active muscle edema (STIR/T2) from chronic fibrofatty replacement (T1/Dixon):
  Calpainopathy (LGMDR1): Selective, symmetrical fatty degeneration of the gluteus maximus, adductor magnus, semimembranosus, and biceps femoris; marked sparing of the rectus femoris, gracilis, and sartorius (“sartorius sparing” sign). In the shoulder girdle, the posterior deltoid, latissimus dorsi, and serratus anterior show preferential involvement.
  Dysferlinopathy (LGMDR2): Early, prominent fatty replacement of the posterior calf muscles, with the medial head of the gastrocnemius and soleus affected before the lateral head, creating a characteristic “diamond-shaped” calf involvement pattern, while the tibialis anterior is preserved until late stages; in the thigh, vastus lateralis and adductor magnus are heavily infiltrated.
  Sarcoglycanopathies (LGMDR3-R6): Diffuse, extensive fatty replacement of the hip adductors, glutei, quadriceps, and hamstrings, presenting an imaging pattern identical to Duchenne and Becker muscular dystrophies.
• Molecular Genetic Testing (NGS Panels / Whole Exome Sequencing): Next-generation sequencing (NGS) utilizing targeted multigene neuromuscular panels (>50–100 genes) or whole exome/genome sequencing (WES/WGS) represents the gold standard definitive diagnostic modality. High-resolution copy number variant (CNV) analysis via multiplex ligation-dependent probe amplification (MLPA) or chromosomal microarray is mandatory to detect large exonic deletions or duplications missed by standard short-read sequencing.
• Muscle Biopsy (Histopathology, Immunohistochemistry, & Western Blot): Indicated when genetic testing reveals variants of uncertain significance (VUS) or fails to identify biallelic mutations in suspected recessive disease:
  Routine Histology (H&E, Modified Gomori Trichrome): Reveals the classic dystrophic triad: marked variability in myofiber diameter with round atrophic and hypertrophic fibers, internal/central nuclei in >3% of fibers, ongoing myofiber necrosis with active phagocytosis, basophilic regenerating fibers, dense endomysial fibrosis, and extensive adipocyte replacement.
  Immunohistochemistry (IHC) & Multiplex Western Blot: Monoclonal antibodies evaluate the sarcolemmal presence of alpha-, beta-, gamma-, and delta-sarcoglycan, dysferlin, calpain-3, dystrophin (rod, C-terminal, N-terminal domains), and telethonin. Western blotting provides definitive protein quantification and molecular weight sizing, confirming loss of functional protein.
• Cardiopulmonary Testing:
  12-Lead Electrocardiogram (ECG): Screen for PR interval prolongation, bundle branch blocks, pathologic Q waves, and baseline repolarization abnormalities.
  24- to 48-Hour Ambulatory Holter Monitoring: Screen for intermittent AV block, paroxysmal atrial fibrillation, and non-sustained ventricular tachycardia; mandatory annual screening in LMNA carriers.
  Transthoracic Echocardiography (TTE) & Cardiac MRI (cMRI): Quantifies left ventricular ejection fraction (LVEF), end-diastolic volumes, and segmental wall motion abnormalities. Cardiac MRI with late gadolinium enhancement (LGE) detects early myocardial fibrosis, particularly mid-wall fibrotic striae in LMNA patients.
  Comprehensive Pulmonary Function Testing (PFTs): Spirometry measuring Forced Vital Capacity (FVC) in both seated and supine positions; a drop in supine FVC >15–20% relative to sitting FVC is diagnostic of significant diaphragmatic weakness. Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) quantify respiratory pump strength, and Peak Cough Flow (PCF) assesses airway clearance capability.

7. Classification

The classification of limb-girdle muscular dystrophies was redefined during the 229th European Neuro-Muscular Centre (ENMC) International Consensus Workshop (2018). Under this modernized framework, the historical alphanumeric nomenclature (LGMD1A–1I for dominant, LGMD2A–2Z for recessive) was replaced by a precise system designating the condition as “LGMD”, followed by the inheritance pattern (“D” for dominant, “R” for recessive), the chronological order of genetic discovery, and the affected protein name in parentheses:

8. Treatment

Medical / Nonoperative

Physical Therapy & Exercise Prescription: Nonoperative management forms the cornerstone of daily care. Physical therapy must emphasize regular, low-to-moderate intensity submaximal aerobic exercise (such as stationary recumbent cycling, aquatic therapy, and level treadmill walking). High-resistance strength training, heavy plyometrics, and eccentric muscle loading (e.g., downhill running or loaded eccentric squats) are strictly contraindicated; high mechanical strain induces immediate sarcolemmal tearing, acute rhabdomyolysis, and permanent myofiber drop-out. Daily home passive stretching programs targeting the gastrocnemius-soleus complex, hamstrings, and hip flexors are vital to retard contracture progression.

Orthotic Management: Custom ankle-foot orthoses (AFOs) are indicated to address progressive foot drop, improve toe clearance during the swing phase of gait, and enhance dynamic stability during stance. Articulated AFOs with dorsiflexion assist or lightweight ground-reaction AFOs are preferred over rigid, solid AFOs; locking the ankle joint in a rigid neutral position eliminates compensatory ankle mechanics and may precipitate knee buckling in patients with concurrent quadriceps weakness. Knee-ankle-foot orthoses (KAFOs) are generally poorly tolerated due to severe proximal hip extensor and abductor weakness.

Respiratory Management: Regular spirometric surveillance (measuring seated and supine FVC every 6 to 12 months) is essential. Initiation of nocturnal non-invasive positive pressure ventilation (NIV / BiPAP) is indicated when FVC falls below 50% of predicted, supine FVC drops by >20% relative to upright FVC, or symptoms of nocturnal hypoventilation (morning headaches, daytime fatigue) appear. Mechanical insufflation-exsufflation (cough assist) is initiated when peak cough flow falls below 270 L/min, ensuring effective clearance of bronchial secretions during acute upper respiratory tract infections.

Cardiac Pharmacotherapy & Electrophysiology: Early introduction of cardioprotective pharmacotherapy, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNI), and beta-blockers, is recommended upon detection of subclinical left ventricular remodeling. In laminopathy (LGMDD1 / LMNA), prophylactic implantable cardioverter-defibrillator (ICD) placement is indicated per 2022 ESC guidelines for patients with PR prolongation, high-grade AV block, non-sustained ventricular tachycardia, or LVEF <50%, given the high incidence of sudden cardiac death.

Investigational Molecular & Gene Therapies: Recombinant adeno-associated virus (rAAV) mediated gene replacement therapies (e.g., AAVrh74.MHCK7.SGCB / SRP-9003 for beta-sarcoglycanopathy / LGMDR4, and AAV-mediated alpha-sarcoglycan / LGMDR3) have demonstrated sustained sarcolemmal transgene expression and functional stabilization in early clinical trials. Emerging CRISPR-Cas9 genome editing and exon-skipping platforms represent active translational avenues.

Operative

Goals of Surgery: The primary goals of orthopaedic surgery in limb-girdle muscular dystrophy are: (1) maintain independent or assisted upright ambulation; (2) correct fixed joint contractures that destabilize stance; (3) stabilize progressive spinal deformities to preserve pulmonary volume and upright sitting balance; and (4) restore periscapular stability to augment upper extremity functional reach.

Primary Surgical Procedures:

• Achilles Tendon Lengthening (TAL): Percutaneous Hoke triple hemisection, Vulpius gastrocnemius recession, or open Z-lengthening for fixed equinus deformity. Correction must be titrated carefully to achieve neutral (0°) dorsiflexion without over-lengthening. Postoperative management requires immediate weightbearing in rigid walking boots or casts within 24 to 48 hours to avert disuse atrophy.
• Hamstring & Iliotibial Band Lengthening: Fractional lengthening of the semimembranosus and semitendinosus combined with distal iliotibial band fasciotomy (Yount release) to eliminate fixed knee flexion and hip flexion-abduction contractures.
• Posterior Spinal Fusion (PSF) with Segmental Instrumentation: Multi-rod pedicle screw instrumentation spanning from upper thoracic levels (T2–T4) to the pelvis (sacrum/ilium via S2-alar-iliac screws) in non-ambulatory patients with pelvic obliquity, or ending at L5 in select ambulatory patients. Corrects coronal deformity, restores sagittal balance, and prevents thoracic cage collapse.
• Scapulothoracic Arthrodesis / Scapulopexy: Arthrodesis of the medial scapular border to the underlying posterior ribs (ribs 3 to 6) using heavy cerclage cables or reconstruction plates augmented with autograft and allograft; alternatively, soft-tissue scapulopexy using synthetic tethering or tendon graft to anchor the scapula to the ribs or spine. Restores a rigid scapular base of support, allowing the deltoid to achieve active forward elevation and abduction.

Indications & Contraindications

Explicit Numerical Indications:

• Fixed Equinus Contracture: Fixed equinus deformity >10° with inability to achieve neutral (0°) ankle dorsiflexion, causing severe toe-walking, stance-phase knee recurvatum, or frequent tripping in an ambulatory patient.
• Fixed Knee Flexion Contracture: Fixed knee flexion contracture >15°–20° that increases quadriceps mechanical load and triggers dynamic knee buckling during stance.
• Fixed Hip Flexion Contracture: Thomas test demonstrating hip flexion contracture >20°–30° with severe compensatory lumbar hyperlordosis.
• Neuromuscular Scoliosis: Progressive spinal curvature with Cobb angle >40°–50°, progressive loss of sitting balance, pelvic obliquity >15°, or progressive thoracic cage distortion in growing children or non-ambulatory adolescents.
• Scapular Winging: Severe functional impairment with active forward elevation restricted to <90° due to periscapular stabilizer failure, in the presence of functional deltoid strength (grade ≥4/5 on MRC scale) and full passive glenohumeral range of motion.

Contraindications:

• Critical Pulmonary Compromise: Preoperative FVC <30% of predicted without established, patient-adapted non-invasive ventilation (NIV) protocols and dedicated postoperative intensive care support.
• Uncontrolled Cardiac Instability: Decompensated congestive heart failure, uncorrected high-grade AV block, or uncontrolled ventricular tachyarrhythmias (absolute contraindications to elective orthopaedic surgery).
• Non-Ambulatory Burned-Out Contractures: Long-standing, painless contractures in non-ambulatory patients where surgical release provides no functional, nursing, or seating benefit.
• Achilles Tendon Over-Lengthening: Surgical over-lengthening that eliminates plantarflexion tension, converting equinus into a calcaneus gait, leads to catastrophic, permanent loss of ambulation in patients with already weakened quadriceps.

9. Outcome

Ambulation Maintenance & Functional Longevity: Timely surgical release of lower extremity joint contractures (Achilles tendon lengthening and hamstring/ITB release) combined with immediate postoperative weightbearing extends independent or assisted ambulation by an average of 1.5 to 3 years in properly selected patients. Preserving upright mobility retards the onset of severe scoliosis, reduces osteoporosis, and enhances psychosocial well-being.

Scoliosis Correction & Seating Stability: Posterior spinal fusion with rigid segmental instrumentation halts curve progression, corrects pelvic obliquity to <5°, restores sagittal balance, and eliminates progressive trunk collapse. Fusion stabilizes thoracic volume, mitigating the mechanical contribution to restrictive pulmonary decline, and achieves high caregiver satisfaction regarding seating balance and nursing ease.

Scapulothoracic Arthrodesis Functional Gains: Solid scapulothoracic fusion provides an average gain of 35° to 50° in active shoulder forward elevation (improving functional reach from 75°–85° preoperatively to 120°–135° postoperatively). Patients achieve statistically significant improvements in Disabilities of the Arm, Shoulder, and Hand (DASH) and American Shoulder and Elbow Surgeons (ASES) scores, restoring independence in self-feeding, facial hygiene, and overhead reaching.

Disuse Muscle Atrophy & Recumbency Hazard: Dystrophic muscle possesses severely impaired regenerative reserve. Prolonged bed rest (>48–72 hours) accelerates myofiber proteolysis and fibrofatty replacement, resulting in loss of up to 1% to 2% of muscle volume per day. Marginally ambulatory patients subjected to prolonged recumbency or non-weightbearing plaster immobilization frequently suffer permanent, irreversible loss of independent ambulation.

10. Complications

Complications associated with limb-girdle muscular dystrophy and its operative management are categorized by onset chronometry:

11. Pearls and Pitfalls

• Universal Total Intravenous Anesthesia (TIVA): Treat every patient with LGMD as high-risk for anesthetic-induced rhabdomyolysis and hyperkalemic arrest; strictly prohibit succinylcholine and volatile halogenated inhalational agents, relying exclusively on propofol, opioids, dexmedetomidine, and non-depolarizing muscle relaxants reversed with sugammadex under train-of-four monitoring.
• Enforce Immediate Weightbearing Within 24–48 Hours: Following lower extremity soft-tissue releases or tendon lengthening, immobilize the limbs in rigid walking casts or boots and initiate weightbearing standing or walking within 24 to 48 hours postoperatively to prevent irreversible disuse muscle atrophy.
• Systematic Cardiopulmonary Clearance in Every Subtype: Always perform baseline 12-lead ECG, 24-hour Holter monitoring, echocardiogram, and both sitting and supine spirometry preoperatively, regardless of the severity of limb weakness; subclinical cardiomyopathy and diaphragmatic weakness are frequently occult.
• Supine vs. Sitting Spirometric Comparison: A postural reduction in FVC >15–20% when moving from sitting to supine is the most sensitive early clinical indicator of diaphragmatic weakness, predicting impending nocturnal hypoventilation and post-extubation respiratory failure.
• Titrated Sparing Achilles Lengthening: Never lengthen the Achilles tendon beyond neutral dorsiflexion (0°); residual mild tightness is preferable to over-lengthening, which eliminates the plantarflexion push-off lever arm and destabilizes the knee into dynamic buckling.
• Avoid Prescribing High-Intensity Eccentric Exercise: Subjecting dystrophic muscle to aggressive resistance training or eccentric loading causes extensive sarcolemmal tearing, acute rhabdomyolysis, and permanent loss of contractile fibers; exercise regimens must be strictly low-to-moderate intensity, submaximal, and concentric.
• Do Not Enforce Prolonged Non-Weightbearing Cast Immobilization: Placing a dystrophic patient in non-weightbearing plaster casts for 4 to 6 weeks after tendon lengthening guarantees rapid disuse atrophy and frequently converts an ambulatory patient into permanent wheelchair dependence.
• Do Not Confuse LGMD with Inflammatory Myopathy (Polymyositis): Endomysial mononuclear inflammation on biopsy is common in dysferlinopathy and calpainopathy and is frequently misdiagnosed as polymyositis; empiric high-dose corticosteroid therapy causes steroid myopathy, rapid weight gain, and accelerated loss of function without clinical benefit.
• Do Not Overlook LMNA Conduction Defects: Overlooking subtle palpitations or presyncope in a patient with LGMDD1 (LMNA) risks fatal sudden cardiac death; urgent cardiac rhythm evaluation and early ICD implantation are lifesaving.

12. Controversy

Timing of Surgical Contracture Release (Early Prophylactic vs. Late Established): Significant debate exists regarding whether soft-tissue contractures should be released early when mild (e.g., fixed equinus 5°–10°) to preserve physiological gait mechanics, or delayed until severe deformity severely impairs ambulation. Proponents of early release emphasize that eliminating equinus prevents compensatory knee hyperextension and falls; opponents contend that any surgical trauma, immobilization, and postoperative downtime accelerate the natural progression of muscular weakness.

Scapulothoracic Arthrodesis vs. Non-Fusion Scapulopexy: Controversy persists regarding the ideal surgical technique for stabilizing the winged scapula. Osseous scapulothoracic arthrodesis provides superior, permanent mechanical stability and higher functional gains in forward elevation, but is associated with substantial complication rates including pneumothorax, rib fractures, nonunion, and chest wall constriction. Soft-tissue scapulopexy (using synthetic mesh, tendon allografts, or suture anchors) avoids bony fusion and pulmonary morbidity, but exhibits a higher rate of progressive stretching, recurrence of winging, and loss of overhead reach over time.

Corticosteroid Efficacy Across LGMD Subtypes: Unlike Duchenne muscular dystrophy where glucocorticoids represent a standard disease-modifying therapy, the role of corticosteroids in LGMD remains unproven and controversial. While small case series suggest transient functional stabilization in select sarcoglycanopathies (LGMDR3-R6) and dysferlinopathies, prospective randomized trials are lacking, and the substantial risks of steroid-induced myopathy, rapid weight gain, and osteopenia often outweigh potential benefits.

Systemic AAV Vector Safety and High-Dose Immunogenicity: With emerging recombinant adeno-associated virus (AAV) gene therapies entering clinical trials for sarcoglycanopathies and other LGMD subtypes, intense debate centers on the safety of high-dose systemic intravenous vector delivery. High systemic vector burdens carry serious risks of acute hepatotoxicity, thrombotic microangiopathy, complement activation, and dorsal root ganglion toxicity, while pre-existing or acquired neutralizing antibodies prevent repeat vector administration.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Leone E, Pandyan A, Rogers A et al. Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024. doi:10.1136/jnnp-2023-331988 [Level I: Systematic Review / Meta-Analysis]
• Silva IS, Pedrosa R, Azevedo IG et al. Respiratory muscle training in children and adults with neuromuscular disease. Cochrane Database Syst Rev. 2019. doi:10.1002/14651858.CD011711.pub2 [Level I: Systematic Review / Cochrane Meta-Analysis]
• Mendell JR, Rodino-Klapac LR, Rosales-Quintero X et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 2009. doi:10.1002/ana.21732 [Level I: Randomized Controlled Trial (Phase I/IIa Gene Transfer)]
• Katja Zeppenfeld, Jacob Tfelt‐Hansen, Marta Riva et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022. doi:10.1093/eurheartj/ehac262 [Level V (Expert Conceptual Review): Clinical Practice Guideline / Expert Consensus]
• Joanna S. Amberger, Carol A. Bocchini, François Schiettecatte et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Research. 2014. doi:10.1093/nar/gku1205 [Level V (Expert Conceptual Review): Comprehensive Genomic & Phenotypic Knowledge Repository]

15. Master Class Pro-Tip

Surgical intervention in limb-girdle muscular dystrophy demands absolute adherence to two non-negotiable principles: anesthetic vigilance and rapid functional re-mobilization. First, an uncompromising total intravenous anesthesia (TIVA) regimen must be executed without exposure to succinylcholine or volatile halogenated anesthetics, which can precipitate catastrophic rhabdomyolysis and hyperkalemic arrest. Second, the surgeon must combat disuse muscle atrophy with extreme urgency. Dystrophic muscle loses contractile mass at an alarming rate during bed rest; a patient who is kept non-weightbearing for several weeks may never walk again. Following contracture releases or tendon lengthening, immobilize the extremity in rigid, well-padded walking splints or weightbearing casts and mobilize the patient within 24 to 48 hours postoperatively. Preoperatively, always secure formal cardiopulmonary clearance with sitting and supine spirometry and dedicated cardiac rhythm evaluation, ensuring that subclinical cardiomyopathy or diaphragmatic weakness is addressed before entering the operative suite.

Master Class Surgical Pearl: Perioperative Management and Functional Preservation in Muscular Dystrophies